An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
But the group has chosen the tough immuno-oncology space for its third attempt to woo the big players.
39% of the patients assessed carried this biomarker, the conference presentation reveals.